Snipd home pageGet the app
public
The Readout Loud chevron_right

239: 2022 in review, CEO indictments, & the year ahead

Dec 22, 2022
29:27
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
1
Introduction
00:00 • 2min
chevron_right
2
Cyderdine CEO Nader Porhasen and a Related Executive
02:19 • 2min
chevron_right
3
Best and Worst Biotech CEOs of the Year
04:04 • 3min
chevron_right
4
Biotech CEOs - Did I Miss Anyone?
06:41 • 2min
chevron_right
5
The Cost Effectiveness of the Cannon Map in Alzheimer's Disease
09:02 • 3min
chevron_right
6
Biotech Index Down 30% for the Year
12:05 • 3min
chevron_right
7
What's Next for Personalized Cancer Vaccine?
15:04 • 3min
chevron_right
8
Is the IRA a Headwind for Gene Therapy?
18:03 • 3min
chevron_right
9
Gene Therapy for Rare Diseases
21:21 • 3min
chevron_right
10
Covid-19
24:21 • 2min
chevron_right
11
COVID-19 Podcast - The Last for 2023
25:54 • 2min
chevron_right
12
What Do You Think of Them?
27:43 • 2min
chevron_right
We look back on the biggest biotech stories of 2022 and how, despite some meaningful advances in Alzheimer's disease and gene therapy, the industry seems stuck in a sentiment rut. We also discuss the latest news in the life sciences, including a pair of indicted CEOs and the debate over how much an oft-debated new medicine should cost.
HomeTop podcastsPopular guestsTop books